Holen Sie sich die Stockscreener-App
1.12
1.75%
-0.02
Handel nachbörslich:
1.11
-0.01
-0.89%
Schlusskurs vom Vortag:
$1.14
Offen:
$1.1101
24-Stunden-Volumen:
28,864
Relative Volume:
0.94
Marktkapitalisierung:
$15.66M
Einnahmen:
$37.79M
Nettoeinkommen (Verlust:
$-10.38M
KGV:
-8.6154
EPS:
-0.13
Netto-Cashflow:
$-1.00M
1W Leistung:
-6.67%
1M Leistung:
-10.40%
6M Leistung:
-25.83%
1J Leistung:
-32.93%
1-Tages-Spanne:
$1.09
$1.1999
1-Wochen-Bereich:
$1.07
$1.21
52-Wochen-Spanne:
$1.07
$2.3587
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Firmenname
Cumberland Pharmaceuticals Inc
Sektor
Telefon
615-255-0068
Adresse
2525 WEST END AVENUE, NASHVILLE,, TN
Vergleichen Sie CPIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CPIX | 1.12 | 15.66M | 37.79M | -10.38M | -1.00M | -0.13 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2012-11-12 | Bestätigt | UBS | Neutral |
| 2011-02-01 | Bestätigt | UBS | Neutral |
| 2010-12-16 | Herabstufung | UBS | Buy → Neutral |
| 2010-08-17 | Herabstufung | Jefferies | Buy → Hold |
| 2010-08-17 | Bestätigt | Morgan Joseph | Buy |
| 2010-08-17 | Bestätigt | UBS | Buy |
| 2010-05-14 | Bestätigt | Morgan Joseph | Buy |
Alle ansehen
Cumberland Pharmaceuticals Inc Aktie (CPIX) Neueste Nachrichten
Cumberland Pharma stock hits 52-week low at $1.07 - Investing.com
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2024 Earnings Call Transcript - MSN
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Cumberland Partners Ltd - MarketBeat
Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) - Yahoo Finance UK
Cumberland Pharmaceuticals Inc. (CPIX) Quarterly 10-Q Report - Quartzy
Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ... By GuruFocus - Investing.com Canada
Cumberland: Q3 Earnings Snapshot - mySA
Cumberland Pharmaceuticals Reports Q3 2024 Earnings and Developments - TipRanks
Cumberland Pharmaceuticals Inc (CPIX) Reports Q3 2024 Revenue of $9.1 Million and EPS Loss of $0.11 - GuruFocus.com
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update - PR Newswire
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire UK
Cumberland's Ifetroban Secures Dual FDA Designations for Rare DMD Treatment | CPIX Stock | CPIX Stock News - StockTitan
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - PR Newswire
Cumberland Pharmaceuticals director James Jones buys $1,827 in stock - Investing.com
Cumberland Pharmaceuticals CEO A.J. Kazimi buys $1,827 in stock - Investing.com
Cumberland Pharmaceuticals director Caroline Young acquires $913 in stock - Investing.com
Cumberland Pharmaceuticals director James Jones buys $1,827 in stock By Investing.com - Investing.com UK
Cumberland's Caldolor Shows 78% Better Safety Than Ketorolac in Landmark 150K Patient Study | CPIX Stock News - StockTitan
New Study Compares Caldolor® (ibuprofen injection) to ketorolac - PR Newswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS - Citizentribune
Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight - PR Newswire UK
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? - Simply Wall St
Cumberland Pharma stock hits 52-week low at $1.18 By Investing.com - Investing.com Australia
Cumberland Pharma stock hits 52-week low at $1.18 - Investing.com India
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size, Share Analysis And Growth Statistics By 2033 - WhaTech
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - India Shorts
Bacterial Pneumonia Market Expected to See Prominent Growth - openPR
Complicated Skin And Skin Structure Infections Drugs Market Insights Discussed Regarding Share, Trends, Siz... - WhaTech
Idiopathic Pulmonary Fibrosis Ipf Market Size and Growth - openPR
Scleroderma Market to Witness Significant Growth by 2031 | Pfizer, Inc., Sanofi, GlaxoSmithKline plc - openPR
Cumberland Pharma stock hits 52-week low at $1.19 By Investing.com - Investing.com Australia
Cumberland Pharma stock hits 52-week low at $1.19 - Investing.com
Vasopressin Market Huge Growth in Future Scope 2024-2031 | Par - openPR
Shareholders have faith in loss-making Phathom Pharmaceuticals (NASDAQ:PHAT) as stock climbs 6.6% in past week, taking one-year gain to 74% - Simply Wall St
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com - Defense World
Scleroderma Diagnostics and Therapeutics Market – 37% of Growth to Originate from APAC -Actelion Pharmaceuticals, Inc., – உங்கள் குரல் - உங்கள் குரல்
Cooling Paste Market Growing Rapidly by-Kobayashi Pharmaceutical, Hisamitsu Pharmaceutical, Pigeon, New Tac Kasei, Sato – IndiaPolitics.com - IndiaPolitics.com
Ibuprofen Injection Industry to Witness Massive Growth (2024-2034) |Cumberland Pharmaceuticals, CSL Limited, Akorn, Inc. – IndiaPolitics.com - IndiaPolitics.com
Cooling Paste Industry to Witness an Outstanding Growth by 2030 |Kobayashi Pharmaceutical, Hisamitsu Pharmaceutical, Pig – IndiaPolitics.com - IndiaPolitics.com
Drugs for Xerostomia Market Future Developments – Concordia, AMICI, Aurobindo Pharma Ltd, Impax Labs - Cauverynews
Burn Pain Market Expected to Experience Major Growth by 2034, - openPR
Burn Pain Market Expected to Experience Major Growth by 2034, According to DelveInsight | Cumberland Pharma, Janssen R&D, Cephalon - Barchart
Nasal Polyposis Drug Market Research Report 2023-2087 - KnowCasino
Scleroderma Global Market Report Detailed by 2024: Forecast And Share 2033 - WhaTech
Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire
Idiopathic Pulmonary Fibrosis Market Forecasted - openPR
Global Asthma Treatment Market to Cross ~USD 32 Billion by 2030 | DelveInsight - GlobeNewswire
Scleroderma Market Size, Share, Growth Insights and Report - openPR
Methotrexate Injection Market Specialized New Report, See - openPR
Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated by Analysts at StockNews.com - Defense World
Finanzdaten der Cumberland Pharmaceuticals Inc-Aktie (CPIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):